COXFA4
ENSG00000189043
Target class
Enzyme
Chromosome
7
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- COXFA4
- Gene name
- Cytochrome c oxidase associated subunit FA4
- Gene symbol
- COXFA4
- Previous gene symbols
- NDUFA4
- Protein name
- Cytochrome c oxidase subunit FA4 (Complex I-MLRQ) (CI-MLRQ) (Cytochrome c oxidase subunit NDUFA4) (NADH-ubiquinone oxidoreductase MLRQ subunit)
- MLRQ
- CI-9k
- MRCAF1
- MISTR1
- Gene biotype
- Protein coding
- Gene family
- Mitochondrial complex IV: cytochrome c oxidase subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 366.62
- Tissue specificity (Gini)
- 0.279
- Tissue specificity (tau)
- 0.59
- KEGG gene identifiers
- hsa:4697
- Protein interaction confidence
- 0.924773
- Protein interaction partners
- 97
- R-HSA-5628897
- R-HSA-611105
- R-HSA-9707564
- R-HSA-9864848
- End position
- 10940531
- Start position
- 10931943
- Chromosome
- 7
- Strand
- Reverse
- Mitochondrion inner membrane
- Single-pass membrane protein .
- Mitochondria
- PubMed 23746447
- PubMed 30030519
- Tissue specificity (tau)
- 0.589664
- Expression inequality (Gini)
- 0.278634
Expression in transcripts per million
- Heart - Atrial Appendage
- 366.62
- Heart - Left Ventricle
- 353.88
- Brain - Frontal Cortex (BA9)
- 342.53
- Muscle - Skeletal
- 293.62
- Brain - Cortex
- 270.44
Expression in transcripts per million
- Heart - Atrial Appendage366.62
- Heart - Left Ventricle353.88
- Brain - Frontal Cortex (BA9)342.53
- Muscle - Skeletal293.62
- Brain - Cortex270.44
- Artery - Coronary261.48
- Brain - Anterior cingulate cortex (BA24)256.31
- Brain - Cerebellar Hemisphere251.38
- Brain - Amygdala247.37
- Artery - Tibial242
- Brain - Nucleus accumbens (basal ganglia)227.95
- Brain - Cerebellum226.33
- Artery - Aorta215.81
- Kidney - Medulla205.34
- Brain - Substantia nigra194.51
- Brain - Hippocampus193.92
- Brain - Caudate (basal ganglia)191.15
- Brain - Putamen (basal ganglia)169.4
- Brain - Spinal cord (cervical c-1)145.8
- Brain - Hypothalamus143.24
- Esophagus - Gastroesophageal Junction140.65
- Uterus139.53
- Esophagus - Muscularis138.33
- Colon - Sigmoid135.75
- Fallopian Tube134.18
And 29 more, listed on the interactive page.
- GO:0005739
- GO:0005743
- GO:0031966
- GO:0045277
- GO:0005515
- GO:0008137
- GO:0044877
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor